U.S. Thyroid Cancer Diagnostics Market to 2032

Overview

The U.S. Thyroid Cancer Diagnostics Market is expected to reach a 4,002.99 USD Billion by 2032 and is projected to grow at a CAGR of 10.29% from 2025 to 2032.

Revenue, 2024 (USD Billion)
2,312.69
Forecast, 2032 (USD Billion)
4,002.99
CAGR, 2024 - 2032
10.29%
Report Coverage
U.S.

U.S. Thyroid Cancer Diagnostics Market 2018-2032 USD Billion

U.S. Thyroid Cancer Diagnostics Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 2,312.69 USD Billion
  • Projected Market Size (2032): 4,002.99 USD Billion
  • CAGR (2025-2032): 10.29%

Key Findings of U.S. Thyroid Cancer Diagnostics Market

  • The U.S. Thyroid Cancer Diagnostics Market was valued at 2,312.69 USD Billion in 2024.
  • The U.S. Thyroid Cancer Diagnostics Market is likely to grow at a CAGR of 10.29% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Papillary Carcinoma in Cancer Type Segment accounted for the largest share of the market with a revenue of 1,819.49 USD Billion
  • The fastest growing segment Hospitals in End User Segment grew Fastest with a CAGR of 12.02% during the forecast period from 2024 to 2032.

U.S. Thyroid Cancer Diagnostics Market Scope

U.S. Thyroid Cancer Diagnostics Market Segmentation & Scope
Product Type
  • Consumables & Accessories
  • Instruments
Test Type
  • Others
  • Biopsy
  • Blood Test
  • Imaging Test
Age Group
  • Below 21
  • 21-29
  • 65 and above
  • 30-65
Stages
  • Stage IV
  • Stage III
  • Stage II
  • Stage I
Cancer Type
  • Others
  • Follicular Carcinoma
  • Papillary Carcinoma
End User
  • Others
  • Cancer Research Institutes
  • Diagnostic Imaging Centers
  • Independent Diagnostic Laboratories
  • Associated Labs
  • Hospitals
Distribution Channel
  • Retail Sales
  • Direct Tender

U.S. Thyroid Cancer Diagnostics Market Data Coverage Insights

Study Period 2024-2032
Base Year 2021
Unit Revenue in USD Billion
Market Value in 2024 2,312.69 USD Billion
Market Value in 2032 4,002.99 USD Billion
CAGR (2025-2032) 10.29%
Historic Data 2016-2023
Market Segments Covered Product Type,Test Type,Age Group,Stages,Cancer Type,End User,Distribution Channel

Regional Insights:

  • Leading Market (2024-2032): U.S., leading in terms of revenue 2,312.69 USD Billion in 2024
    • Key Country: U.S., leading in terms of revenue with value of 2,312.69 USD Billion in 2024.

Segments and Scope

  • U.S. Thyroid Cancer Diagnostics Market to 2032, By Product Type
    • Instruments is the largest segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a revenue of 1,502.42 USD Billion in the year 2024.
    • Instruments is the Fastest growing segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a Growth rate of 10.54 % in forecast period 2025-2032.
  • U.S. Thyroid Cancer Diagnostics Market to 2032, By Test Type
    • Imaging Test is the largest segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a revenue of 993.66 USD Billion in the year 2024.
    • Imaging Test is the Fastest growing segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a Growth rate of 11.02 % in forecast period 2025-2032.
  • U.S. Thyroid Cancer Diagnostics Market to 2032, By Age Group
    • 30-65 is the largest segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a revenue of 1,041.55 USD Billion in the year 2024.
    • 30-65 is the Fastest growing segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a Growth rate of 10.90 % in forecast period 2025-2032.
  • U.S. Thyroid Cancer Diagnostics Market to 2032, By Stages
    • Stage I is the largest segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a revenue of 945.44 USD Billion in the year 2024.
    • Stage I is the Fastest growing segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a Growth rate of 11.09 % in forecast period 2025-2032.
  • U.S. Thyroid Cancer Diagnostics Market to 2032, By Cancer Type
    • Papillary Carcinoma is the largest segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a revenue of 1,819.49 USD Billion in the year 2024.
    • Papillary Carcinoma is the Fastest growing segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a Growth rate of 10.43 % in forecast period 2025-2032.
  • U.S. Thyroid Cancer Diagnostics Market to 2032, By End User
    • Hospitals is the largest segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a revenue of 670.35 USD Billion in the year 2024.
    • Hospitals is the Fastest growing segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a Growth rate of 12.02 % in forecast period 2025-2032.
  • U.S. Thyroid Cancer Diagnostics Market to 2032, By Distribution Channel
    • Direct Tender is the largest segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a revenue of 1,547.72 USD Billion in the year 2024.
    • Direct Tender is the Fastest growing segment in U.S. Thyroid Cancer Diagnostics Market to 2032 with a Growth rate of 10.47 % in forecast period 2025-2032.

U.S. Thyroid Cancer Diagnostics Market Company Share Analysis

 
Company Name Company Share Analysis
Illumina, Inc.
Koninklijke Philips N.V.
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Canon Inc.
U.S. Thyroid Cancer Diagnostics Market Company Share Analysis

U.S. Thyroid Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Thyroid Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Thyroid Cancer Diagnostics Market Company Profiling

U.S. Thyroid Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The U.S. Thyroid Cancer Diagnostics Market is segmented based on Segmentation Product Type,Test Type,Age Group,Stages,Cancer Type,End User,Distribution Channel.
U.S. Thyroid Cancer Diagnostics Market was valued at USD 2,312.69(Revenue in USD Billion) in 2021.
U.S. Thyroid Cancer Diagnostics Market is projected to grow at a CAGR of 10.29% during the forecast period of 2024 to 2032.
The Papillary Carcinoma segment is expected to dominate the U.S. Thyroid Cancer Diagnostics Market, holding a largest market share of 1,819.49 USD Billion in 2024

U.S. Thyroid Cancer Diagnostics Market Scope

U.S. Thyroid Cancer Diagnostics Market Segmentation & Scope
Product Type
  • Consumables & Accessories
  • Instruments
Test Type
  • Others
  • Biopsy
  • Blood Test
  • Imaging Test
Age Group
  • Below 21
  • 21-29
  • 65 and above
  • 30-65
Stages
  • Stage IV
  • Stage III
  • Stage II
  • Stage I
Cancer Type
  • Others
  • Follicular Carcinoma
  • Papillary Carcinoma
End User
  • Others
  • Cancer Research Institutes
  • Diagnostic Imaging Centers
  • Independent Diagnostic Laboratories
  • Associated Labs
  • Hospitals
Distribution Channel
  • Retail Sales
  • Direct Tender
Frequently Asked Questions
The U.S. Thyroid Cancer Diagnostics Market is segmented based on Segmentation Product Type,Test Type,Age Group,Stages,Cancer Type,End User,Distribution Channel.
U.S. Thyroid Cancer Diagnostics Market was valued at USD 2,312.69(Revenue in USD Billion) in 2021.
U.S. Thyroid Cancer Diagnostics Market is projected to grow at a CAGR of 10.29% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Thyroid Cancer Diagnostics Market for final year is USD 4,002.99 (USD Billion).

U.S. Thyroid Cancer Diagnostics Market Company Profiling

U.S. Thyroid Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The U.S. Thyroid Cancer Diagnostics Market is segmented based on Segmentation Product Type,Test Type,Age Group,Stages,Cancer Type,End User,Distribution Channel.
U.S. Thyroid Cancer Diagnostics Market was valued at USD 2,312.69(Revenue in USD Billion) in 2021.
U.S. Thyroid Cancer Diagnostics Market is projected to grow at a CAGR of 10.29% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Thyroid Cancer Diagnostics Market for final year is USD 4,002.99 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.